# Laurus Labs (LAURUSLABS) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/lauruslabs

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,340
- Change: -0.26%
- As of: 2026-11-06
- 1D return: -0.26%
- 5D return: -2.72%
- 1M return: +17.12%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

Laurus Labs (₹2,340.00) maintains a robust multi-timeframe uptrend as of 2026-11-06, trading above all key moving averages and the Supertrend on daily, weekly, and monthly charts. The monthly trend is exceptionally strong (ADX 84.42), while the daily trend is established (ADX 26.89). Price sits near the upper end of recent ranges (+80% in the last 20 days; +93.3% over the last year), reflecting significant momentum with YTD returns of +110.7%. However, the stock has pulled back slightly from its recent high of ₹2,365.27 (1.08% away), forming an active Inside Bar pattern that signals consolidation. Immediate support rests at the pivot level of ₹2,326.73 (-0.57%), with further downside levels at ₹2,307.47 and ₹2,268.93. Resistance is immediate at ₹2,365.27, followed by ₹2,384.53. Anomalies from late October showed extreme volume-backed upward moves, but current activity suggests a pause. A break above ₹2,365.27 would confirm continuation, while a close below ₹2,326.73 could signal short-term weakness.

- Trend Structure: Bullish across daily, weekly, and monthly horizons; price is above all major moving averages and the Supertrend.
- Momentum & Positioning: Strong long-term performance (YTD +110.7%, 1Y +138.8%) with price in the top 7% of its 1-year range.
- Key Levels: Immediate resistance at ₹2,365.27 (+1.08%); immediate support at ₹2,326.73 (-0.57%).
- Pattern & Risk: Active 'Inside Bar' indicates consolidation; annualized volatility is +33.7% with a current drawdown of -2.7%.

- Inside Bar
- Hammer
- Bullish Engulfing Reversal
- Bearish Engulfing Reversal
- Evening Star

### News Context

Laurus Labs has demonstrated significant price momentum in early November 2026, with shares surging over 20% on November 1 as part of a broader market outperformance alongside peers like Piramal Pharma and Ather Energy. This specific stock movement aligns with a wider sectoral trend where Indian pharmaceutical equities have emerged as the best-performing segment for the year, delivering up to 112% returns for leading stocks by November 5. According to Economic Times reporting, this rally is underpinned by resilient domestic demand, improving margins in US business operations, and emerging opportunities in products such as semaglutide. While analysts characterize the earnings recovery as predictable and the rally as sustainable, they also caution that current valuations may constrain further market-beating gains relative to other sectors.

- Laurus Labs shares surged more than 20% on November 1, 2026, contributing to broader market outperformance.
- The company is among pharma leaders delivering up to 112% returns year-to-date through November 5, 2026.
- Sector outperformance is attributed to resilient domestic demand, improved US margins, and new product pipelines like semaglutide.
- Analysts view the rally as sustainable due to predictable earnings but warn that valuations could limit further upside compared to other sectors.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Dividend alert! Last day to buy Power Grid, NTPC, Info Edge among 26 stocks for dividend rewards](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-power-grid-ntpc-info-edge-among-26-stocks-for-dividend-rewards/articleshow/135555888.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)

### What Changed

On November 6, 2026, Laurus Labs Limited filed a routine notice with the National Stock Exchange (NSE) regarding the publication of shareholder notices for its interim dividend. The company confirmed that the Board had previously approved an interim dividend of Re. 1.00 per equity share, representing a 50% payout on the Rs. 2.00 face value. This filing establishes November 6, 2026, as the record date for determining eligible shareholders. The submission specifically addresses the requirement to provide tax-deduction-at-source (TDS) documentation related to this distribution. While this confirms the administrative timeline for the dividend payment, it does not indicate any new strategic shifts or changes to the company's operational profile.

- Record Date: November 6, 2026 is designated as the record date for the interim dividend.
- Dividend Amount: The Board-approved interim dividend stands at Re. 1.00 per equity share (50% of Rs. 2.00 face value).
- Filing Purpose: The NSE submission serves as a procedural notice for TDS document publication and does not signal new corporate actions.

- [Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LAURUSLABS_06112026110554_NewsPubTDS06112026.pdf)

### Fundamentals

Laurus Labs demonstrates a sharp acceleration in financial performance for Q2 FY2026-27, with revenue rising 33% year-on-year to ₹2,206 crore and net profit nearly doubling to ₹436 crore. This follows a strong full-year trend where TTM sales reached ₹7,823 crore and net profit surged to ₹1,332 crore. Earnings quality improved significantly, evidenced by Cash from Operating Activity jumping to ₹1,624 crore in FY2026 and CFO/EBITDA reaching 107%, indicating that reported profits are converting robustly into cash.

However, this growth is accompanied by increasing working capital intensity. Inventory Days rose to 317 days in Mar 2026, and Trade Receivables increased to ₹2,242 crore as of Sep 2026. Consequently, the Cash Conversion Cycle lengthened to 263 days, and cash reserves declined sharply from ₹49.8 crore to ₹24.5 crore over the same period. While the balance sheet remains debt-reduced (Borrowings fell to ₹2,518 crore in Mar 2026), the company is investing heavily in capacity expansion, with CWIP rising to ₹1,282 crore. Foreign Institutional Investors have increased their stake to 30.84%, signaling market confidence in the growth trajectory despite liquidity tightening.

- Q2 FY2026-27 Revenue grew 33% YoY to ₹2,206 crore; Net Profit doubled to ₹436 crore.
- Earnings quality strengthened: FY2026 CFO reached ₹1,624 crore with 107% conversion of operating profit.
- Working capital pressure visible: Inventory Days rose to 317 and Cash Conversion Cycle extended to 263 days in Mar 2026.
- Cash reserves halved to ₹24.5 crore as of Sep 2026, while CWIP expanded to ₹1,282 crore.

### Bull Case

Laurus Labs demonstrates strong technical momentum and sector tailwinds as of November 6, 2026. The stock is trading at ₹2,340.0 with a market capitalization of approximately ₹1,267.57 billion. Technical indicators across daily, weekly, and monthly timeframes are uniformly bullish, with the Supertrend direction signaling an uptrend on all three horizons. The stock has delivered significant returns, including +110.7% year-to-date and +138.8% over the past year, supported by resilient domestic demand and improving US business margins. While valuations may limit further market-beating gains compared to other sectors, the underlying earnings recovery and new product opportunities, such as semaglutide, provide a constructive foundation for continued outperformance if these operational drivers remain intact.

- Technical indicators show a bullish consensus across daily, weekly, and monthly timeframes, with the Supertrend direction positive on all horizons as of November 6, 2026.
- The stock has achieved a year-to-date return of +110.7% and a one-year return of +138.8%, reflecting strong momentum within a sectoral index that rose 27% in 2026.
- Underlying earnings recovery is supported by resilient domestic demand, improving US business margins, and emerging opportunities in products like semaglutide.
- Analysts view the rally as sustainable due to predictable earnings, though they caution that current valuations may cap further relative outperformance compared to broader market peers.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Dividend alert! Last day to buy Power Grid, NTPC, Info Edge among 26 stocks for dividend rewards](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-power-grid-ntpc-info-edge-among-26-stocks-for-dividend-rewards/articleshow/135555888.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LAURUSLABS_06112026110554_NewsPubTDS06112026.pdf)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)

### Bear Case

Laurus Labs faces valuation and volatility risks despite strong recent performance. The stock has surged 110.7% year-to-date and 138.8% over the past year, with analysts cautioning that such elevated valuations may limit further market-beating gains. Technically, the share price is trading near immediate resistance at ₹2,365.27 (1.08% above current levels), suggesting potential upside friction. Furthermore, the stock exhibits high volatility, with an annualized volatility of 33.7% and a maximum drawdown of -18.7%, indicating significant price swings that could impact short-term returns.

- Valuation caution: Analysts warn that current valuations, following a 110.7% YTD rally, may cap further outperformance relative to other sectors.
- Resistance proximity: The stock is within 1.08% of its nearest technical resistance level at ₹2,365.27, posing a near-term upside barrier.
- High volatility profile: Annualized volatility stands at 33.7% with a historical maximum drawdown of -18.7%, reflecting substantial price risk.
- Recent momentum reversal: After a +18.8% gain over the last 10 days, the stock posted a -0.3% return on the latest session, closing at ₹2,340.00.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Dividend alert! Last day to buy Power Grid, NTPC, Info Edge among 26 stocks for dividend rewards](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-power-grid-ntpc-info-edge-among-26-stocks-for-dividend-rewards/articleshow/135555888.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LAURUSLABS_06112026110554_NewsPubTDS06112026.pdf)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)

### FAQs

**What is the interim dividend amount and record date for Laurus Labs?**

The Board of Directors has approved an interim dividend of Re. 1.00 per equity share (50% of the Rs. 2.00 face value). The record date for this payout is November 6, 2026.

**How has Laurus Labs performed in 2026 compared to its sector?**

Laurus Labs is among the leading performers in India's pharmaceutical sector, which rose 27% year-to-date. The stock delivered returns of up to 112% in 2026, driven by resilient domestic demand, improving US business margins, and new product opportunities like semaglutide.

**What are the key technical support and resistance levels for the stock?**

As of November 6, 2026, with the stock closing at ₹2,340.00, immediate support sits at ₹2,326.73 (pivot) and ₹2,307.47 (low). Resistance levels are located at ₹2,365.27, ₹2,384.53, and ₹2,423.07.

**What is the current trend direction for Laurus Labs on daily and monthly timeframes?**

Technical indicators show a bullish trend on both daily and monthly timeframes as of November 6, 2026. The stock has gained +110.7% year-to-date and +138.8% over the past year, though it experienced a recent 1-day decline of -0.3%.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Dividend alert! Last day to buy Power Grid, NTPC, Info Edge among 26 stocks for dividend rewards](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-power-grid-ntpc-info-edge-among-26-stocks-for-dividend-rewards/articleshow/135555888.cms)
- [Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/LAURUSLABS_06112026110554_NewsPubTDS06112026.pdf)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- [SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RE 1 PER SHARE |FACE VALUE:2 |RECORD DATE:06-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-](https://www.nseindia.com/companies-listing/corporate-filings-actions)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹2,326.73
- Risk regime: Price Risk Requires Attention

### Support levels
- 1811.7
- 1769.4
- 1342.9

### Resistance levels
- 2441.9
- 2365.2666666666664
- 2384.5333333333333

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.26% |
| return_10 | +18.78% |
| return_1m | +14.15% |
| return_1y | +138.82% |
| return_20 | +17.12% |
| return_3m | +27.87% |
| return_5 | -2.72% |
| return_6m | +98.71% |
| return_since_start | 2.800860878746041 |
| return_ytd | +110.73% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -18.69% |
| annualized_volatility | +33.74% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Laurus Labs Limited Q2 FY2026-27: PBT rises 23% QoQ

For the quarter ended 30 September 2026, Laurus Labs reported revenue from operations of ₹2,206 crore, up 8.9% sequentially, and profit before tax (PBT) of ₹592 crore, up 22.9%. Basic EPS increased to ₹8.17 from ₹6.81 in Q1 FY2026-27 and ₹3.61 in Q2 FY2025-26. Operating cash flow was ₹805 crore, but investing outflows of ₹863 crore left free cash flow negative at ₹58 crore.

## Revenue and expenses

Revenue from operations rose by ₹180 crore from ₹2,026 crore in Q1 FY2026-27. Total income was ₹2,219 crore, including ₹13 crore of other income. Total expenses increased 4.7% sequentially to ₹1,628 crore, below the rate of revenue growth.

Q2 expenses included ₹901 crore for materials consumed, ₹374 crore of other expenses, ₹266 crore in employee benefits and ₹127 crore of depreciation and amortisation.

## Profit and tax

PBT increased to ₹592 crore from ₹481 crore in Q1 FY2026-27, while profit for the period rose 20.5% to ₹436 crore from ₹362 crore. Tax expense was ₹155 crore, comprising current tax of ₹163 crore and a deferred tax credit of ₹7.9 crore.

Profit attributable to owners of the parent was ₹441 crore; non-controlling interests recorded a loss of ₹5.3 crore. Basic EPS of ₹8.17 was 20.0% higher sequentially and 126.3% above Q2 FY2025-26. Diluted EPS was ₹8.16.

## Cash flow and capital investment

Operating activities generated ₹805 crore in Q2 FY2026-27. Investing activities used ₹863 crore and financing activities used ₹30 crore. On the reported free-cash-flow measure—operating cash flow plus investing cash flow—free cash flow was negative ₹58 crore.

Capital work in progress stood at ₹1,282 crore on 30 September 2026, up from ₹773 crore on 31 March 2026. Property, plant and equipment was ₹3,847 crore, compared with ₹3,873 crore at the March year-end. The higher work-in-progress balance shows that more capital projects remained under development at quarter-end.

## Balance sheet and working capital

Total assets were ₹11,514 crore on 30 September 2026, compared with ₹10,511 crore on 31 March 2026. Over the same dates, inventories increased to ₹2,659 crore from ₹2,342 crore and trade receivables rose to ₹2,242 crore from ₹2,155 crore. Trade payables were ₹1,301 crore, up from ₹1,252 crore.

Cash and cash equivalents declined to ₹24 crore from ₹113 crore at the March year-end. Current liabilities rose to ₹3,954 crore, including current financial liabilities of ₹3,581 crore. Together, the higher inventory and receivables balances and increased current liabilities indicate a larger working-capital and short-term-liability footprint at the reporting date.

## Key Takeaway

Laurus Labs delivered faster sequential growth in PBT than in revenue, with EPS also more than doubling year on year. However, investing outflows exceeded operating cash generation, leaving free cash flow negative, while work in progress and working-capital balances increased. The key investor consideration is how earnings growth translates into cash generation as these balances evolve.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +27.47%
- FII holding: +28.00%
- DII holding: +13.73%
- Mutual fund holding: +10.15%
- Retail holding: +12.64%
- Promoter pledged: +0.00%

### Major reported shareholders

- M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava) — +22.98% (Partnership Firms)
- MIRAE ASSET LARGE & MIDCAP FUND — +4.33%
- NEW WORLD FUND INC — +4.28%
- ANUKAR PROJECTS PRIVATE LIMITED — +3.24%
- SMALLCAP WORLD FUND, INC — +2.77%
- CHUNDURU VENKATA LAKSHMANA RAO — +2.65%
- BARCLAYS WEALTH TRUSTEES INDIA PRIVATE LIMITED — +1.55%
- AKASH BHANSHALI — +1.32%
- M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram) — +1.15% (Partnership Firms)
- KOTAK FUNDS - INDIA MIDCAP FUND — +1.01%

## Official filings

- 2026-11-06 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-06 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-06 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_06112026110554_NewsPubTDS06112026.pdf)
- 2026-11-06 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-05 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-05 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-05 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-04 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-04 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-04 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-03 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_03112026113343_Transcript03112026.pdf)
- 2026-11-03 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-02 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-02 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-11-02 — Corporate Action Notice: Laurus Labs Limited - Ex-Date: 06-Nov-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-10-30 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_14417_WebXMLFile_20261030_141911670.xml)
- 2026-10-30 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_30102026142617_NewsAd30102026.pdf)
- 2026-10-29 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026145355_Outcome29102026.pdf)
- 2026-10-29 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026150128_Galenvs.pdf)
- 2026-10-29 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026150634_SIandC.pdf)
- 2026-10-29 — Earnings Presentation: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026151833_InvPresentation29102026.pdf)
- 2026-10-29 — Generic Announcement: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026151316_Dividend29102026.pdf)
- 2026-10-29 — Press Release: Laurus Labs Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/LAURUSLABS_29102026153754_1PressRelease29102026.pdf)

## News and market events

- 2026-11-07 — Economic Times: **More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles** — India's family-run pharmaceutical companies, including Laurus Labs, Granules India, Bharat Biotech, Sun Pharma, and Torrent Pharma, are undergoing costly long-term strategic shifts toward complex generics, biologics, and advanced therapeutics as the next generation assumes larger leadership roles. These successors are committing significant capital to capabilities requiring deeper scientific expertise and longer gestation periods, moving away from traditional low-cost manufacturing models. The success of these transitions remains uncertain, with returns expected over decades rather than quarte — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/more-than-family-business-drugmakers-make-costly-long-term-strategic-shifts-as-next-generation-steps-into-bigger-roles/articleshow/135644313.cms)
- 2026-11-07 — Economic Times: **Diwali 2026 wealth creators: 8 BSE 500 stocks shrug off market weakness, deliver up to 191% returns; do you own any?** — Eight BSE 500 stocks, including Aditya Infotech and HFCL, delivered returns exceeding 100% since Diwali 2025, outperforming the broader market which saw the Nifty 50 decline nearly 3%. As Indian equities enter Samvat 2083, brokerages such as ICICI Direct and Motilal Oswal remain constructive, projecting earnings-led growth with double-digit EPS expansion expected in FY27. These firms favor selective investments in sectors like banking, manufacturing, and consumption, citing improved valuations and fundamental delivery as key drivers for future returns. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/diwali-2026-wealth-creators-8-bse-500-stocks-shrug-off-market-weakness-deliver-up-to-191-returns-do-you-own-any/articleshow/135628626.cms)
- 2026-11-06 — Economic Times: **MSCI rebalancing on Monday: Adani Energy, Groww set for big inflows; RIL, Jio Financial may face outflows** — MSCI's latest rebalancing, with revised weights effective September 1, is expected to drive significant trading activity in Indian stocks, particularly during the final 30 minutes of Monday's session. Adani Energy Solutions and Groww are among the additions set to receive substantial inflows, while Reliance Industries and Jio Financial Services face potential outflows due to weight reductions. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/msci-rebalancing-on-monday-adani-energy-groww-set-for-big-inflows-ril-jio-financial-may-face-outflows/articleshow/133626232.cms)
- 2026-11-06 — Mint: **Lighting up your Diwali! Cupid, HFCL, Sterlite Tech, MTAR: 10 multibagger stocks that soared over 150% in Samvat 2082** — Despite a challenging Samvat 2082 marked by benchmark declines and geopolitical tensions, 16 Nifty 500 stocks gained over 100%, with Cupid and Sterlite Technologies leading with returns of 570% and 556% respectively. This performance highlights a significant divergence in stock-specific returns against the broader market weakness, as noted by PL Capital. Looking ahead to Samvat 2083, Kotak Neo suggests that while short-term volatility may persist due to global uncertainties, supportive corporate earnings and attractive entry points could offer long-term wealth creation opportunities for discip — [Source](https://www.livemint.com/market/stock-market-news/lighting-up-your-diwali-cupid-hfcl-sterlite-tech-mtar-10-multibagger-stocks-that-soared-over-150-in-samvat-2082-11793956981821.html)
- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-11-05 — Economic Times: **Dividend alert! Last day to buy Power Grid, NTPC, Info Edge among 26 stocks for dividend rewards** — With November 6 set as the record date for dividend payouts, today marks the final trading day under SEBI's T+1 settlement cycle for investors to purchase shares and become eligible for corporate actions. Twenty-six companies, including Power Grid, NTPC, and Info Edge, are turning ex-record date on Friday, with interim dividends ranging from Rs 0.05 to Rs 10 per share. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-power-grid-ntpc-info-edge-among-26-stocks-for-dividend-rewards/articleshow/135555888.cms)
- 2026-11-01 — MONEYCONTROL: **Broader markets outperform; Ather Energy, Piramal Pharma, Laurus Labs surge over 20% each** — Shares of Ather Energy, Piramal Pharma, and Laurus Labs surged by more than 20% each, contributing to broader market outperformance. — [Source](https://www.moneycontrol.com/news/business/markets/broader-markets-outperform-ather-energy-piramal-pharma-laurus-labs-surge-over-20-each-14065365.html)
- 2026-10-30 — CNBC-TV18: **FIIs return to buying Indian stocks with ₹3,599 crore inflows; DIIs turn net sellers** — Foreign institutional investors purchased shares worth ₹3,598.54 crore on a provisional basis on Friday, marking a reversal from Thursday's net selling of ₹943.60 crore. Concurrently, domestic institutional investors sold equities worth ₹817.51 crore, contrasting with their net buying position on the previous day. — [Source](https://www.cnbctv18.com/market/fiis-return-to-buying-indian-stocks-with-rs3599-crore-inflows-diis-turn-net-sellers-20023622.htm)
- 2026-10-30 — CNBC-TV18: **Sensex, Nifty extend gains for 2nd day: IT stocks lead rally, broader market underperforms** — Indian equity benchmarks extended gains for a second consecutive session, driven by buying in information technology stocks and select heavyweight shares, although the broader market underperformed. Specific stock movements were attributed to quarterly results, analyst notes, and management changes. — [Source](https://www.cnbctv18.com/market/sensex-nifty-extend-gains-for-2nd-day-it-stocks-lead-rally-broader-market-underperforms-20023387.htm)
- 2026-10-30 — Economic Times: **Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY** — Laurus Labs reported Q2FY27 financial results showing a 126% YoY increase in net profit to Rs 441 crore and a 33% YoY rise in revenue to Rs 2,206 crore. The company also declared an interim dividend of Re 1 per share. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/laurus-labs-shares-climb-4-after-q2-profit-zooms-126-yoy/articleshow/135343867.cms)
- 2026-10-30 — Mint: **Laurus Labs share price at record high after Q2 results 20⁠⁩26, dividend announcement - Should you buy pharma stock?** — Laurus Labs reported Q2FY27 revenue of ₹2,206 crore and net profit of ₹441 crore, while announcing an interim dividend of Re 1 per share and operationalizing a new commercial-scale peptide manufacturing plant in Vizag. — [Source](https://www.livemint.com/market/stock-market-news/laurus-labs-share-price-at-record-high-after-q2-results-20-26-dividend-announcement-should-you-buy-pharma-stock-11793343724383.html)
- 2026-10-29 — The Hindu: **Laurus Labs Q2 net profit surges on 33% rise in revenue** — Laurus Labs reported a more than twofold increase in Q2 consolidated net profit to ₹436.74 crore on a 33% revenue rise, while declaring an interim dividend and approving strategic acquisitions in Canada and Hyderabad. The company also operationalized its first commercial-scale peptide plant in Visakhapatnam to address surging demand for peptide therapeutics. — [Source](https://www.thehindu.com/business/Industry/laurus-labs-q2-net-profit-surges-on-33-rise-in-revenue/article71641412.ece)
- 2026-10-29 — FREEPRESSJOURNAL.IN: **Laurus Labs Q2 Net Profit More Than Doubles To ₹441 Crore; To Acquire Stakes In Galenvs Science And SI&C Resins** — Laurus Labs reported that its Q2 FY27 net profit more than doubled to Rs 441 crore, driven by growth in CDMO and affordable medicine segments. The company simultaneously announced definitive agreements to acquire a 60% stake in Galenvs Science and a 52% stake in SI&C Resins to expand its oligonucleotide and peptide manufacturing capabilities. — [Source](https://www.freepressjournal.in/business/laurus-labs-q2-net-profit-more-than-doubles-to-441-crore-to-acquire-stakes-in-galenvs-science-and-sic-resins)
- 2026-10-29 — Times of India: **Laurus Labs Q2 net profit surges 126% backed by growth in CDMO, affordable medicines businesses | Hyderabad News - The Times of India** — Laurus Labs Ltd reported a 126% year-on-year increase in Q2 FY27 net profit to ₹441 crore and a 33% rise in revenue to ₹2,206 crore, supported by strong performance in its CDMO and affordable medicines divisions. The company also announced investments to expand its technology platforms through acquisitions of stakes in Galenvs Sciences and SI&C Resins. — [Source](https://timesofindia.indiatimes.com/city/hyderabad/laurus-labs-q2-net-profit-surges-126-backed-by-growth-in-cdmo-affordable-medicines-businesses/articleshow/135317979.cms)
- 2026-10-29 — FREEPRESSJOURNAL.IN: **Sensex Surges 905 Points, Nifty Closes At 22,936.75; Know- What Drove The Sharp Market Recovery?** — Indian equity markets ended the session with significant gains as the Sensex surged 905.01 points to close at 74,151.04 and the Nifty 50 advanced 237.90 points to settle at 22,936.75. The recovery was primarily driven by renewed buying interest in banking, FMCG, and real estate sectors, although individual stock performance varied based on quarterly earnings and management commentary. — [Source](https://www.freepressjournal.in/business/sensex-surges-905-points-nifty-closes-at-2293675-know-what-drove-the-sharp-market-recovery)
- 2026-10-29 — FREEPRESSJOURNAL.IN: **Laurus Labs Posts Strong Q2 FY27 Results With ₹441 Crore Net Profit, Expands Capabilities With Galenvs Sciences Acquisition** — Laurus Labs Limited announced a 126% rise in Q2 FY27 net profit to ₹441 crore and declared an interim dividend of ₹1.00 per share. The company also signed a definitive agreement to acquire a 60% stake in Galenvs Sciences to enhance its oligonucleotide development and manufacturing capabilities. — [Source](https://www.freepressjournal.in/business/laurus-labs-posts-strong-q2-fy27-results-with-441-crore-net-profit-expands-capabilities-with-galenvs-sciences-acquisition)
- 2026-10-29 — MONEYCONTROL: **Laurus Labs Q2 results: Net profit jumps 126% on CDMO surge; buys Canadian firm to deepen oligonucleotide play** — Laurus Labs reported a 126% jump in net profit for the second quarter, driven by a surge in its Contract Development and Manufacturing Organization (CDMO) business. Additionally, the company acquired a Canadian firm to expand its capabilities in oligonucleotides. — [Source](https://www.moneycontrol.com/news/business/earnings/laurus-labs-q2-results-net-profit-jumps-126-on-cdmo-surge-buys-canadian-firm-to-deepen-oligonucleotide-play-14063621.html)
- 2026-10-29 — The Hindu: **Laurus Labs’ Q2 Results: Net more than doubles at ₹441 cr** — Laurus Labs’ net profit more than doubled at Rs 441 crore in the second quarter of the current financial year ended September compared to Rs 195 crore. — [Source](https://www.thehindubusinessline.com/news/laurus-labs-q2-net-more-than-doubles-at-441-cr/article71640046.ece)
- 2026-10-29 — BUSINESSTODAY: **Laurus Labs shares close higher as Q2 net profit jumps 126%** — Laurus Labs Ltd reported a 126% year-on-year increase in consolidated net profit to Rs 441 crore for Q2 FY27, driven by strong performance in its CDMO and affordable medicines divisions. The company also announced plans to invest over Rs 3,000 crore across manufacturing network and capability expansion during FY27 and FY28. — [Source](https://www.businesstoday.in/markets/stocks/story/laurus-labs-shares-rise-3-after-q2-results-net-profit-jumps-126-to-rs-441-crore-564549-2026-10-29)
- 2026-10-29 — CNBC-TV18: **Q2 Results Live Updates: Suzlon, Asian Paints, Trent, Laurus report today; Vedanta, Hero react** — Q2 Results LIVE Updates: Asian Paints, Trent, Coal India, Indigo, Suzlon, Blue Star, IEX, GCPL, Laurus Labs, Strides Pharma, Vedanta Power and many other companies report numbers today. Watch this space for all the live quarterly result updates. — [Source](https://www.cnbctv18.com/market/q2-results-live-updates-trent-asian-paints-suzlon-cil-indigo-ambuja-blue-star-gcpl-laurus-iex-strides-pidilite-vedanta-hero-usl-share-price-liveblog-20021974.htm)
- 2026-10-28 — BUSINESSTODAY: **JioBlackRock MF folios jump 261%: Can new fund houses challenge established AMCs?** — JioBlackRock Mutual Fund's investor folios surged 261% year-on-year to 13.37 lakh in September 2026, highlighting the rapid expansion of newer fund houses in India's competitive mutual fund industry. — [Source](https://www.businesstoday.in/mutual-funds/story/jioblackrock-mf-folios-jump-261-can-new-fund-houses-challenge-established-amcs-563522-2026-10-29)
- 2026-10-28 — BUSINESSTODAY: **Soumya Chava on Laurus Labs’ push into finished-dose drugs** — Laurus Labs is looking to expand its finished-dose medicines business and contract manufacturing operations as Soumya Chava leads growth plans for its affordable medicines division. — [Source](https://www.businesstoday.in/magazine/profile/story/soumya-chava-on-laurus-labs-push-into-finished-dose-drugs-564225-2026-10-28)
- 2026-10-26 — Mint: **Top 3 stocks to buy tomorrow: Laurus Labs, MCX, Coforge by market expert; check stop-loss, target price for Tue, 27 Oct** — India’s benchmark indices ended a four-session losing streak, with the Nifty 50 rising 0.68% and the Sensex 0.66%. Gains were limited by elevated oil prices and uncertainty ahead of the US Federal Reserve decision. Analysts highlighted key technical levels and recommended Laurus Labs, MCX , Coforge. — [Source](https://www.livemint.com/market/stock-market-news/top-3-stocks-to-buy-tomorrow-laurus-labs-mcx-coforge-by-market-expert-check-stop-loss-target-price-for-tue-27-oct-11793014330701.html)
- 2026-10-21 — MONEYCONTROL: **Chartist Talk: Will Nifty 50’s technical rebound sustain? Milan Vaishnav advises holding Laurus Labs, Shyam Metalics** — Milan Vaishnav,Nifty 50,NSE Nifty,Laurus Labs,Shyam Metalics and Energy,Bharat Heavy Electricals,FSN E-Commerce Ventures Nykaa, — [Source](https://www.moneycontrol.com/news/business/markets/chartist-talk-will-nifty-50-s-technical-rebound-sustain-milan-vaishnav-advises-holding-laurus-labs-shyam-metalics-14056271.html)
- 2026-10-19 — BUSINESS: **Laurus Labs zooms 128% from March low; hits new high in weak market** — Laurus Labs Q2 outlook: On the EBITDA front, analysts at Kotak Institutional Equities build in 67% YoY growth to ₹680 crore in Q2FY27 with EBITDA margin expansion of 680 bps to 31.2%. — [Source](https://www.business-standard.com/markets/news/laurus-labs-share-price-zooms-128-from-march-low-hits-new-high-in-weak-market-126101900354_1.html)

## Business profile

**Strategic vision:** Research-driven pharmaceutical and biotechnology company with global operations.

### Business segments
- **Pharmaceutical Ingredients:** Global supplier of Active Pharmaceutical Ingredients (APIs) and intermediates, with a focus on anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics, emphasizing backward integration.
- **Finished Dosages:** Integrates API manufacturing with R&D for finished dosage forms, operating a state-of-the-art oral finished dosage facility in Visakhapatnam, India.
- **Advanced Biologics:** Enters the biologics and biotechnology products space through its subsidiary Laurus Bio, investing in Cell and Gene therapies for healthcare and nutritional sectors.
- **Contract Development & Manufacturing Organization (CDMO):** Provides CDMO services in India for generic and proprietary drug development and manufacturing programs for global pharmaceutical and biotech companies, with Laurus Synthesis focusing on these services.

### Competitive strengths
- Backward integration capabilities within API operations.
- Global presence with manufacturing facilities and R&D centers in India and offices internationally.
- Subsidiary ecosystem focused on specialized areas like CDMO and advanced biologics.

## Related stocks

- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%
- [Dr. Reddy's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/drreddy) — +0.51%
- [Glenmark Pharmaceuticals Limited (Healthcare)](https://faxioms.com/stocks/glenmark) — +4.36%
- [Lupin Limited (Healthcare)](https://faxioms.com/stocks/lupin) — +0.01%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/lauruslabs
Markdown representation: https://faxioms.com/stocks/lauruslabs?render=md